James Healy
Managing Partner at Sofinnova Investments
United States
Overview
Work Experience
Managing Partner
2000 - Current
James Healy, M.D., PhD. Medical scientist, proven investor and value-added board member with 20+ years’ experience funding tomorrow’s cures. Dr. Healy finances companies in the US and Europe that are developing innovative therapies that can be transformative for patients. At Sofinnova he has funded twelve products that were approved by the FDA or EMA. Twenty-one of his investments have gone public and eleven have been acquired as private or public companies. Jim received a B.A. in Molecular Biology and B.A. Scandinavian Studies from UC Berkeley where he graduated with Honors and received the Departmental Citation. He subsequently completed the Medical Scientist Training Program and received his MD and PhD in Immunology from Stanford University where he was a Beckman Scholar and received the Novartis Foundation Bursary Award. He authored or co-authored thirteen scientific articles and reviews, including three papers published in Nature. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the Biotechnology Industry Organization (BIO) and the National Venture Capital Association (NVCA). Previous investments include Amarin (AMRN), Appelis (APLS), Audentes (BOLD), Cellective, Cotherix (CTRX), Durata (DRTX), Hyperion (HYPN), InterMune (ITMN), Movetis (MOVE), Nextwave, Novacea (NOVA), Preglem, Prestwick, Salveo and Tesaro (TSRO). He currently sits on the board of directors of Ascendis (ASND), Coherus (CHRS), Iterum (ITRM), Natera (NTRA), Nucana (NCNA), Obseva (OBSV) and Y-Mabs (YMAB).
Chairman Of The Board
2019
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
Raised $418,000,000.00 from Sofinnova Partners, Sofinnova Investments, RTW Investments, General Atlantic, Lilly Asia Ventures, Biotechnology Value Fund, Omega Funds, Rock Springs Capital, Perceptive Advisors and Adage Capital Management.
Board Member, Lead Independent Director
2021
Board Member
2019
Karuna Therapeutics is a biopharmaceutical company that develops and delivers medicines for psychiatric and neurological conditions.
Raised $1,598,600,000.00 from PureTech Health, Alexandria Venture Investments, Partner Fund Management, Fidelity, Sands Capital Ventures, Wellcome Trust, Eventide, ARCH Venture Partners, Pivotal bioVenture Partners and Sofinnova Investments.
Board Observer
2018
Board Member
2014
Board Member
2014
Board Member
2014
Board Member
2017
Board Member
2014
Lead Investor
Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment paradigms.
Raised $1,875,733,778.00 from Royalty Pharma and Royalty Pharma.